The BenfoTeam Study
Benfotiamine for Mild Coginitive Impairment (MCI) or Mild Alzheimer's Disease
Researchers at your local university are partnering with the BenfoTeam to test if a drug that increases thiamine intake can help slow cognitive decline.
Study Sites
- Experiencing mild memory concerns or diagnosed with MCI or mild Alzheimer’s disease
- Ages 50-89
- Compensation provided
- Conducted at multiple sites
Study Background
Help advance research on slowing cognitive decline.
BenfoTeam tests if increasing a person’s thiamine (vitamin B1) intake can slow cognitive decline in people with early Alzheimer’s disease (AD), including Mild Cognitive Impairment (MCI) and mild dementia.
The BenfoTeam clinical research trial is based on evidence from decades of research on the role of thiamine in AD. BenfoTeam scientists have found that the brains of people with early AD show a marked thiamine deficiency despite having a sufficient supply of thiamine in their blood.
Fortunately, there is also evidence that this problem with thiamine in the brain may be overcome by boosting the amount of thiamine in the blood far above usual levels. Benfotiamine, a lab-made version of thiamine, is the drug being tested in the BenfoTeam trial.
If you are 50-89 years old with memory concerns, MCI, or early AD, or caring for a loved one who fits this description, you are invited to learn more about this research study. Join BenfoTeam today!
Study Background
Help advance research on slowing cognitive decline.
BenfoTeam tests if increasing a person’s thiamine (vitamin B1) intake can slow cognitive decline in people with early Alzheimer’s disease (AD), including Mild Cognitive Impairment (MCI) and mild dementia.
The BenfoTeam clinical research trial is based on evidence from decades of research on the role of thiamine in AD. BenfoTeam scientists have found that the brains of people with early AD show a marked thiamine deficiency despite having a sufficient supply of thiamine in their blood.
Fortunately, there is also evidence that this problem with thiamine in the brain may be overcome by boosting the amount of thiamine in the blood far above usual levels. Benfotiamine, a lab-made version of thiamine, is the drug being tested in the BenfoTeam trial.
If you are 50-89 years old with memory concerns, MCI, or early AD, or caring for a loved one who fits this description, you are invited to learn more about this research study. Join BenfoTeam today!
Additional Information
The goal of this study is to test whether increasing the amount of the thiamine in the brain can slow down Alzheimer’s-related memory and thinking problems.
You may qualify for a study if you meet the following criteria.
Inclusion Criteria:
- Ages 50-89
- Diagnosed with mild cognitive impairment (MCI) or mild Alzheimer’s disease
- Stable on any medications you are taking for Alzheimer’s disease. (For donepezil (Aricept), Rivastigmine (Exelon), Galantamine (Razadyne), you must be taking the medications for at least 3 months).
- Living in the community (not in a long-term care or skilled nursing facility)
- Willing to participate in the BenfoTeam study for up to 18 months (plus screening)
Your participation will last 18 months and all visits take place at the clinic. You can participate at the site most convenient to you.
The screening process includes memory and thinking tests; a physical examination; brain imaging using MRI; and blood tests. During the study, clinicians will repeat these tests at different points in the BenfoTeam trial. Half of the BenfoTeam study participants are given the study drug, and half are given an inactive pill (called a placebo), to be taken twice a day for the duration of the study.
Yes, participants will be compensated for their time and effort.
There is no cost for you to participate in our research study.